PT - JOURNAL ARTICLE AU - Ogaz, Dana AU - Edney, Jessica AU - Phillips, Dawn AU - Mullen, Dolores AU - Reid, David AU - Wilkie, Ruth AU - Buitendam, Erna AU - Bell, James AU - Lowndes, Catherine M AU - Hughes, Gwenda AU - Fifer, Helen AU - Mercer, Catherine H AU - Saunders, John AU - Mohammed, Hamish TI - Knowledge, uptake and intention to use antibiotic post-exposure prophylaxis and meningococcal B vaccine (4CMenB) for gonorrhoea among a large, online community sample of gay, bisexual and other men who have sex with men in the UK AID - 10.1101/2024.07.08.24310063 DP - 2024 Jan 01 TA - medRxiv PG - 2024.07.08.24310063 4099 - http://medrxiv.org/content/early/2024/07/08/2024.07.08.24310063.short 4100 - http://medrxiv.org/content/early/2024/07/08/2024.07.08.24310063.full AB - Introduction Novel STI prevention interventions, including doxycycline post-exposure prophylaxis (doxyPEP) and meningococcal B vaccination (4CMenB) against gonorrhoea, have been increasingly examined as tools to aid STI control. There is emerging evidence of the efficacy of doxyPEP in preventing bacterial STIs; however limited data exist on the extent of use in the UK. We examined self-reported knowledge and use of antibiotic post-exposure prophylaxis (PEP), and intention to use (ITU) doxyPEP and 4CMenB among a large, community sample of gay, bisexual and other men who have sex with men (GBMSM) in the UK.Methods Using data collected by the RiiSH survey (November/December 2023), part of a series of online surveys of GBMSM in the UK, we describe (%, [95% CI]) self-reported knowledge and use of antibiotic PEP (including doxyPEP) and doxyPEP and 4CMenB ITU. Using bivariate and multivariable logistic regression, we examined correlates of ever using antibiotic PEP, doxyPEP ITU, and 4CMenB ITU, respectively, adjusting for sociodemographic characteristics and a composite marker of sexual risk defined as reporting (in the last three months): ≥5 condomless anal sex partners, bacterial STI diagnosis, chemsex, and/or meeting partners at sex-on-premises venues, sex parties, or cruising locations.Results Of 1,106 participants (median age: 44 years [IQR: 34-54]), 34% (30%-37%) knew of antibiotic PEP; 8% (6%-10%) ever reported antibiotic PEP use. Among those who did, most reported use in the last year (84%, 73/87) and exclusively used doxycycline (69%, 60/87). Over half of participants reported doxyPEP ITU (51% [47%-56%]) while over two-thirds (64% [60%-69%]) reported 4CMenB ITU. GBMSM with markers of sexual risk and with uptake of other preventative interventions were more likely to report ever using antibiotic PEP as well as doxyPEP and 4CMenB ITU, respectively. HIV-PrEP users and people living with HIV (PLWHIV) were more likely to report STI prophylaxis use and ITU than HIV-negative GBMSM not reporting recent HIV-PrEP use.Discussion There were high levels of intended use of novel STI prevention interventions. Fewer than one in ten GBMSM had reported ever using antibiotic PEP, with usage more common among those at greater risk of STIs. Future guidelines and health promotion for 4CMenB and antibiotic PEP must be carefully crafted alongside clinical experts and community partners, given intervention complexity and the risk of presenting conflicting public health messages regarding antimicrobial stewardship.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any funding; however, David Reid and Catherine H Mercer were funded as part of The National Institute for Health Research Health Protection Research Unit in Blood Borne and Sexually Transmitted Infections at University College London in partnership with the UK Health Security Agency.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval for this study was granted by the UKHSA Research and Ethics Governance Group (REGG; ref: R&D 524).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data that support the findings of this study are available upon reasonable request from the UK Health Security Agency (UKHSA). Requests can be directed to Dr Hamish Mohammed (riish_survey{at}ukhsa.gov.uk).